Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × ARX788 × Clear all
NCT05018702 2022-06-01

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Fudan University

Phase 2 Unknown
32 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡